It has been hypothesized that selective serotonin reuptake inhibitors (SSRIs), the most common treatment for major depression, affect mood through changes in immune function. However, the effects of SSRIs on inflammatory response are contradictory since these act either as anti-or pro-inflammatory drugs. Previous experimental and clinical studies showed that the quality of the living environment moderates the outcome of antidepressant treatment. Therefore, we hypothesized that the interplay between SSRIs and the environment may, at least partially, explain the apparent incongruence regarding the effects of SSRI treatment on the inflammatory response. In order to investigate such interplay, we exposed C57BL/6 mice to chronic stress to induce a depression-like phenotype and, subsequently, to fluoxetine treatment or vehicle (21 days) while being exposed to either an enriched or a stressful condition. At the end of treatment, we measured the expression levels of several anti-and pro-inflammatory cytokines and inflammatory mediators in the whole hippocampus and in isolated microglia. We also determined microglial density, distribution, and morphology to investigate their surveillance state. Results show that the effects of fluoxetine treatment on inflammation and microglial function, as compared to vehicle, were dependent on the quality of the living environment. In particular, fluoxetine administered in the enriched condition increased the expression of pro-inflammatory markers compared to vehicle, while treatment in a stressful condition produced anti-inflammatory effects. These findings provide new insights regarding the effects of SSRIs on inflammation, which may be crucial to devise pharmacological strategies aimed at enhancing antidepressant efficacy by means of controlling environmental conditions.
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Introduction
Selective serotonin reuptake inhibitors (SSRIs) are the most commonly prescribed drugs for the treatment of major depression (MD), which constitutes an enormous medical, individual, societal and economical challenge and afflicts up to 10-15% of the population worldwide. However, the efficacy of SSRIs is variable and incomplete: 60-70% of patients do not experience remission and 30-40% do not show a significant response (Trivedi et al., 2006) . One of the main reasons for such limited efficacy is the poor comprehension of their mechanisms of action at cellular and molecular levels.
In recent decades, the crosstalk between the innate and adaptive immune systems and the brain has been suggested to represent a key factor in antidepressant drug action (Carvalho et al., 2013; Eller et al., 2008; Lanquillon et al., 2000; Tuglu et al., 2003) . Indeed, treatment with SSRIs has been shown to decrease http://dx.doi.org/10.1016/j.bbi.2016.07.155 0889-1591/Ó 2016 Elsevier Inc. All rights reserved.
